U.S. health advisers are currently debating a novel flu vaccine, the first to leverage the mRNA technology pivotal in combating the COVID-19 pandemic.
Moderna is seeking Food and Drug Administration (FDA) approval for its shot, mFlusiva, targeting individuals aged 50 and older.